Prime Medicine Inc (PRME)
7.085
+0.04
(+0.64%)
USD |
NASDAQ |
May 17, 16:00
7.085
0.00 (0.00%)
After-Hours: 20:00
Prime Medicine Net Income (TTM): -204.50M for March 31, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -204.50M |
| December 31, 2023 | -198.13M |
| September 30, 2023 | -171.77M |
| June 30, 2023 | -150.42M |
| March 31, 2023 | -137.38M |
| Date | Value |
|---|---|
| December 31, 2022 | -121.82M |
| September 30, 2022 | -145.45M |
| June 30, 2022 | -132.51M |
| March 31, 2022 | -105.69M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-204.50M
Minimum
Mar 2024
-105.69M
Maximum
Mar 2022
-151.96M
Average
-145.45M
Median
Sep 2022
Net Income (TTM) Benchmarks
| Pacific Biosciences of California Inc | -296.90M |
| 10x Genomics Inc | -264.30M |
| Recursion Pharmaceuticals Inc | -354.11M |
| Verve Therapeutics Inc | -196.83M |
| Ginkgo Bioworks Holdings Inc | -853.81M |